PFESeagen, a wholly owned subsidiary of PfizerSigning up patients
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Oct 24, 2022
- Main results expected
- Dec 31, 2027
- Fully finished
- Jul 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05253651 · record last updated 2026-07-22 · checked 2026-11-09 15:47 UTC